Prescribe with confidence
Drug Class Analysis GLP-1 Weight Loss Drug Market by Drug Class: Injectable and Dual Agonist Therapies Command 78.4% of Revenue Drug Class Revenue Share, CAGR, and Commercial Drivers GLP-1 Obesity Drug Market 2026 Injectable GLP-1 receptor agonist monoagonists hold a 32.8% GLP-1 market revenue share in 2026 , reflecting Wegovys position as the most commercially successful weight management drug in pharmaceutical history
The molecule may be interesting, but the vial from a research supplier in an unregulated jurisdiction is a different question entirely
What it is: Intravenous delivery of glutathione (the body's "master antioxidant") at doses of 600-2,000mg How it works: 100% bioavailability bypasses gut breakdown, directly supporting cellular detoxification Key benefits: Liver support, energy boost, immune improvement, skin brightening, heavy metal removal Treatment time: 30-60 minutes per session Typical frequency: 1-2 sessions weekly initially, then monthly maintenance The science is compelling